Post Profile






Selexipag in pulmonary arterial hypertension: Added benefit not proven

(Institute for Quality and Efficiency in Health Care) The data in the dossier were unsuitable to show an added benefit: Comparator therapy and division of the population were inadequate.
read more

share
See more about: Health Care

Related Posts


Aflibercept in macular oedema: added benefit not proven

Health : Medical News Today

Neither the new drug nor the comparator therapy was used in accordance with their approvals in the studiesFor the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug afl...

Propranolol in infantile hemangioma: Indication of major added benefit in some patients

Academics / General Science : Science Codex

The Institute for Quality and Efficiency in Health Care (IQWiG) investigated in a dossier assessment whether propranolol offers an added benefit in comparison with the appropriate comparator therapy in infants with proliferating inf...

Talimogene laherparepvec in melanoma: Added benefit not proven

Health : EurekAlert: Health

(Institute for Quality and Efficiency in Health Care) The data from the only study cited by the drug manufacturer in its dossier were unsuitable for the assessment.

Ibrutinib in CLL: Added benefit for treatment-naive patients not proven

Health : EurekAlert: Health

(Institute for Quality and Efficiency in Health Care) The dossier contained no suitable data for any of the three subgroups of treatment-naive patients with chronic lymphocytic leukaemia, for whom the drug was newly approved in 2016...

Saxagliptin and saxagliptin/metformin in type 2 diabetes: Added benefit not proven

Health : EurekAlert: Health

(Institute for Quality and Efficiency in Health Care) The presented analyses of the SAVOR-TIMI 53 study were unsuitable for conclusions on positive or negative effects in comparison with the appropriate comparator therapies.

Comments


Copyright © 2016 Regator, LLC